C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

Use of C1-INH (Berinert) for Renal Allograft Salvage in Refractory Antibody Mediated Rejection

This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing antibody mediated injury. A maximum of 5 patients will be enrolled.

Inclusion Criteria:

• Kidney transplant with acute antibody mediated rejection refractory to standard therapy

Exclusion Criteria:

• Patients with known intolerance of or anaphylaxis to Berinert